Abstracts tagged "Health policy"

Abstract Number: 0177 • ACR Convergence 2023
Cost-Related Medication Non-Adherence Among US Adults with Chronic Arthritis: Trends, Comparisons, and Disparities
Ashkan Ara¹, Matthew Chenoweth¹, Christopher Scannell² and John FitzGerald¹, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA / West Los Angeles VA Medical Center, Los Angeles, CA
Background/Purpose: Cost-related medication non-adherence (CRN), a measure of drug affordability, refers to a patient's inability to adhere to a prescribed medication regimen due to high…
Abstract Number: 0198 • ACR Convergence 2023
Improving Vaccination Uptake of Herpes Zoster in Young Rheumatic Disease Patients Ages 18-49 Using Specialty Pharmacy Partnership
Stephen Lindsey¹, Brittany Hill², Sheela Sheth³ and Arya Loghmani², ¹LSU Health Science Center, New Orleans, LA, ²Louisiana State University, New Orleans, LA, ³Tulane University, New Orleans, LA
Background/Purpose: Herpes zoster (HZ), also known as shingles, causes an estimated one million cases annually in the United States. Many studies have shown that the…
Abstract Number: 0217 • ACR Convergence 2023
Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study
Tali Eviatar¹, Victoria Furer², Ilana Kaufman³, David levartovsky², Ofir Elalouf², Devy Zisman⁴, Tal Gazitt⁵, Amir Haddad⁴, Muna Elias⁶, Joy Feld⁷, Alexandra Balbir-Gurman⁸, Yolanda Braun Moscovici⁹, Sara Pel¹⁰, sharon Nevo¹¹, Daphna Paran² and Ori Elkayam², ¹Tel Aviv Sourasky Medical center, Ramat Gan, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Tel Aviv Medical Center, Petah-Tikva, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Carmel Hospital, Haifa, Israel, ⁶rheumatology unit, Haifa, Israel, ⁷Carmel and Zvulun Medical Centre, Haifa, Israel, ⁸Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ⁹Rambam Heath Care Campus, Haifa, Israel, ¹⁰Tel Aviv Medical Center, Modiin, Israel, ¹¹Tel Aviv Sourasky Medical Center, Givataim, Israel
Background/Purpose: Autoimmune inflammatory rheumatic disease (AIIRD) patients treated with rituximab (RTX) are at risk for severe COVID19 infection, and a blunted humoral response to SARS-CoV-2…
Abstract Number: 0465 • ACR Convergence 2023
The Effects of Post-Dobbs Abortion Policy on Rheumatology Clinical Practice: A Survey of Rheumatologists
Mehret Birru Talabi¹, Bonnie Bermas², Irene Blanco³, Ashira Blazer⁴, Megan Clowse⁵, Cuoghi Edens⁶, Leslie Pierce⁷, Catherine Wright¹ and Rosalind Ramsey-Goldman³, ¹University of Pittsburgh, Pittsburgh, PA, ²UT Southwestern, Dallas, TX, ³Northwestern University, Chicago, IL, ⁴Hospital for Special Surgery, New York, NY, ⁵Duke University, Chapel Hill, NC, ⁶University of Chicago, Chicago, IL, ⁷University of Pittsburgh, Raleigh, NC
Background/Purpose: In June 2022, the U.S. Supreme Court's decision in Dobbs v. Jackson Women's Health removed the federal constitutional right to abortion, returning abortion policy…
Abstract Number: 1019 • ACR Convergence 2023
Association of Historical Redlining and Present-Day Neighborhood Inequities with Missed Outpatient Appointments Among Individuals with Rheumatic Conditions
Sherry Yang¹, Leah Santacroce² and Candace Feldman², ¹Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Structural racism pervades U.S. history with continued effects on health inequities. Residential segregation serves as an example, where redlining maps outlined areas with high…
Abstract Number: 1616 • ACR Convergence 2023
Geographic and Demographic Representation in Industry-sponsored, US-based Clinical Trials of Systemic Lupus Erythematosus Therapies
Joshua Skydel¹, Reshma Ramachandran², Sakinah Suttiratana², Joseph Ross², Joshua Wallach³ and Christopher Burns⁴, ¹Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Yale University, New Haven, CT, ³Emory University, Atlanta, GA, ⁴Dartmouth Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Clinical trials of systemic lupus erythematosus (SLE) therapies have increased over the last decade, driven by evolving knowledge of targetable pathways. However, these trials…
Abstract Number: 2019 • ACR Convergence 2023
2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases
Emma Dures¹, Bayram Farisogullari², Eduardo Santos³, Anna Molto⁴, Caroline Feldthusen⁵, Claire Harris⁶, Corinna Elling-Audersch⁷, Deirdre Conolly⁸, Elena Elefante⁹, Fernando Estévez-López¹⁰, Ilaria Bini¹¹, Jette Primdahl¹², Kirsten Hoeper¹³, Marie Urban¹⁴, Mart van de Laar¹⁵, Marta Redondo¹⁶, Peter Böhm¹⁷, Raj Amarnani¹⁸, Rhys Hayward⁶, Rinie Geenen¹⁹, Simona Rednic²⁰, Susanne Pettersson²¹, Tanja Thomsen²², Till Uhlig²³, Valentin Ritschl²⁴ and Pedro Machado²⁵, ¹Academic Rheumatology, Bristol Royal Infirmary; and Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra (ESEnfC), Coimbra, Portugal, ⁴HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁵Institute of Neuroscience and Physiology, University of Gothenburg, Department of Health and Rehabilitation, Unit of Physiotherapy, Sahlgrenska Academy, Gothenburg, Sweden, ⁶Northwick Park Hospital, London North West University Healthcare NHS Trust, Department of Rheumatology, London, United Kingdom, ⁷Deutsche Rheuma-Liga Bundesverband e.V., Patient Research Partner, Bonn, Germany, ⁸School of Medicine, Trinity College Dublin, Discipline of Occupational Therapy, Dublin, Ireland, ⁹Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ¹⁰Harvard T.H. Chan School of Public Health, Department of Social and Behavioral Sciences, Boston, MA, ¹¹Anmar, Young, Rome, Italy, Rome, Italy, ¹²University Hospital of Southern Denmark, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ¹³Hannover Medical School, Department of Rheumatology and Immunology, Hannover, Germany, ¹⁴University Hospitals Bristol, Research Design Service, Bristol, United Kingdom, ¹⁵University of Twente, Department of Psychology, Health and Technology, Enschede, Netherlands, ¹⁶Camilo José Cela University, Faculty of Heath Sciences, Madrid, Spain, ¹⁷German League against rheumatism, Forschungspartner, Bonn, Germany, ¹⁸Barts Health NHS Trust, Barts Health Rheumatology Service, London, United Kingdom, ¹⁹Utrecht University, Vorstenbosch, Netherlands, ²⁰Prof Dr Simona Rednic, Cluj, Romania, ²¹Karolinska Institute, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ²²University of Copenhagen, Copenhagen Centre for Arthritis Research, Centre for Rheumatology and Spine Diseases VRR, Rigshospitalet, Copenhagen, Denmark, ²³Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²⁴Medical University of Vienna, Vienna, Austria, ²⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom
Background/Purpose: Fatigue is prevalent in people with inflammatory rheumatic and musculoskeletal diseases (I-RMDs) and recognized as one of the most challenging symptoms to manage (1).…
Abstract Number: 2283 • ACR Convergence 2023
Anti-SARS-CoV-2 Vaccination Among Patients Living with Systemic Lupus Erythematosus in Sweden: Coverage and Clinical Effectiveness
Arthur Mageau¹, Julia Simard², Elisabet Svenungsson³ and Elizabeth Arkema⁴, ¹Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden / Internal Medicine Unit, Hopital Bichat, Paris, France, ²Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ³Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Real-world data assessing the effectiveness of the anti-SARS-CoV2 vaccination in patients living with systemic lupus erythematosus (SLE) are currently lacking. We aimed to describe…
Abstract Number: 084 • 2023 Pediatric Rheumatology Symposium
Rheum to Improve: Patient-reported Transition Readiness in a Large Pediatric Rheumatology Clinic
Kristiana Nasto¹, David McDonald¹, Kyla Fergason¹, Mary Robichaux¹, Bernard Danna¹, Monique Maher¹, Alexander Alexander¹, Danielle Guffey¹, Miriah Gillispie-Taylor² and Tiphanie Vogel¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Transition of adolescents with chronic healthcare needs to adult care may result in poor outcomes. We have developed a program to improve the transition…
Abstract Number: L09 • ACR Convergence 2022
Impact on Access to Methotrexate in the Post-Roe Era
Kristin Wipfler¹, Adam Cornish¹, Rebecca Schumacher², Yomei Shaw³, Patricia Katz⁴ and Kaleb Michaud⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases, Santa Fe, NM, ⁴UCSF, San Rafael, CA, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Methotrexate is the first line therapy for RA and is used to treat several other rheumatic and non-rheumatic disorders. In high doses, it can…
Abstract Number: 1430 • ACR Convergence 2022
Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis
Cristiano Moura¹, Luck Lukusa¹, Laura Yan¹, Walter P Maksymowych², Denis Choquette³, Gilles Boire⁴ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: The first biosimilar etanercept (ETA-B) was approved in Canada in 2016, but real-world data comparing the effectiveness of ETA-B versus its equivalent originator (ETA-O)…
Abstract Number: 1782 • ACR Convergence 2022
Sociocultural and Moral Factors Influencing the Decision to Vaccinate Among Rheumatic Patients: A Qualitative Study
Tirsa Colmenares-Roa¹, Amaranta ManriquedeLara², Virginia Pascual Ramos³, JOSE FRANCISCO MOCTEZUMA RIOS⁴, Irazu Contreras-Ibañez⁵, Everardo Alvarez-Hernandez⁶, Guillermo Guaracha Basañez⁷, Graciela Meza-LópezyOlguin⁴ and Ingris Pelaez-Ballestas¹, ¹Hospital General de México "Dr. Eduardo Liceaga", Ciudad de México, Mexico, ²Hospital General de México "Dr. Eduardo Liceaga,", Ciudad de México, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico, ⁴HOSPITAL GENERAL DE MEXICO "Dr. Eduardo Liceaga", Ciudad de México, Mexico, ⁵Instituto Nacional de Nutricion Salvador Zubirán, Ciudad de México, Mexico, ⁶Hospital General de Mexico "Dr.Eduardo Liceaga", Ciudad de México, Mexico, ⁷Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirn", Ciudad de México, Mexico
Background/Purpose: Vaccination is a process that involves individual, social and moral aspects, beyond public governance of vaccines or vaccination as a public health concern. The…
Abstract Number: 2198 • ACR Convergence 2022
How Did a Mandatory Switching Policy for Biosimilars in Canada Impact Uptake and Spending?
Alison McClean¹, Nick Bansback¹, Lucy Cheng¹, Fiona Clemont², Mina Tadrous³, Mark Harrison¹ and Mike Law¹, ¹University of British Columbia, Vancouver, BC, Canada, ²University of Calgary, Calgary, AB, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Uptake of biosimilars has been suboptimal in North America. In 2019, British Columbia (BC) became the first jurisdiction in North America to require patients…
Abstract Number: 0227 • ACR Convergence 2022
The Rheumatology Workforce: Analyzing Geographic and Temporal Variations Among the Rheumatology Physician Workforce in the United States
Kavish Singh¹, Lynn Foster-Johnson², Sladjana Skopelja-Gardner³, Arabi Rasendrakumar⁴, Temitope Ajayi⁵ and Aakanksha Khanna⁶, ¹Montefiore Medical Center, Brooklyn, NY, ²Dartmouth Geisel School of Medicine, Lebanon, NH, ³Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁴University of Buffalo, Buffalo, NY, ⁵University at Buffalo, Buffalo, NY, ⁶Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: To analyze recent trends in the rheumatology workforce related to temporal and national geographic variation in the United States (US). Methods: The publicly available physician workforce…
Abstract Number: 0571 • ACR Convergence 2022
National Rollout of a Medication Safety Dashboard to Improve Testing for Latent Infections Among Biologic/targeted Synthetic DMARD Users Within the Veterans Health Administration: Initial Results
Anna Montgomery¹, Gary Tarasovsky², Mary Whooley², Jennifer Barton³, Karla Miller⁴, Holly Mitchell⁵, Jo Dana², Kimberly Reiter⁶, Elizabeth Wahl⁷, Karine Rozenberg-Ben-Dror⁸, Jing Li⁹ and Gabriela Schmajuk¹⁰, ¹University of California San Francisco, Reno, NV, ²San Francisco VA Medical Center, San Francisco, CA, ³VA Portland Health Care System/OHSU, Portland, OR, ⁴University of Utah Division of Rheumatology/VA Salt Lake City Health Care, Salt Lake City, UT, ⁵Ralph H. Johnson VA Hospital, Mount Pleasant, SC, ⁶Albuquerque VA Medical Center, Albuquerque, NM, ⁷VA Puget Sound Healthcare System, Seattle, WA, ⁸Greater Lakes Region/VISN 12 Dept Veterans Affairs, Hines, IL, ⁹University of California, San Francisco, San Francisco, CA, ¹⁰UCSF / SFVA, San Francisco, CA
Background/Purpose: Guidelines recommend testing for latent hepatitis B virus (HBV), hepatitis C virus (HCV), and tuberculosis (TB) infection prior to initiating biologics or targeted synthetic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].